William M. Grady
M.D., University of Michigan - Ann Arbor, 1990.
B.S., University of Michigan - Ann Arbor, Biomedical Sciences, 1987.
Molecular and cell biology of gastrointestinal cancer: genetic and epigenetic alterations in cancer
Clinical management of gastrointestinal cancer family syndromes
Colon cancer prevention
Biomarkers for colon cancer prevention
Biomarkers for optimizing management of Barretts esophagus
(Reading, Writing, Speaking)
English: (Fluent, Fluent, Fluent)
American Association for Cancer Research
American Association for the Study of Liver Disease
American College of Gastroenterology
American Gastroenterological Association
Honors and Awards
2009, Member, Society of Clinical Investigation
2008-2013, Burroughs Wellcome Clinical Scientist Award in Translational Research, Burroughs Wellcome Fund, Fred Hutchinson Cancer Research Center
2005-2010, Presidential Early Career Award for Scientists and Engineers (PECASE), Department of Veterans Affairs
2002-2005, Mallinckrodt Scholar Award, 42nd Scholar, Edward Mallinckrodt Jr. Foundation
2002-2007, Damon Runyon-Lilly Clinical Investigator Award, Damon Runyon Cancer Research Foundation
2001, John Walsh Memorial GIDH Award in Basic Research, John Walsh Memorial
1997, ADHF Advanced Research Training Award, ADHF
1993, Outstanding Senior Resident Award, University of Michigan
American Society of Clinical Investigation Member, American Society of Clinical Investigation
2000-2004, Assistant Professor, Vanderbilt University, Gastroenterology
1999-1999, Assistant Professor, Case Western Reserve University, Gastroenterology
1998-1999, Instructor, Case Western Reserve University, Gastroenterology
1993-1994, Postdoctoral fellow, Fred Hutchinson Cancer Research Center, Laboratory of D. Hockenbery, M.D., Molecular Biology
Methods and compositions for detecting cancers associated with methylation of hMLH1 promoter DNA, Patent Number: 6858388 B2, 2005, Institution, United States.
Genomic Aberrations Occurring in Subsets of Serrated Colorectal Lesions but not Conventional Adenomas.. Cancer research. 73(9):2863-72.. 2013.
Context is everything for dependence receptors in colorectal cancer.. Proceedings of the National Academy of Sciences of the United States of America. 110(8):2697-8.. 2013.
Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer.. Therapeutic advances in gastroenterology. 5(5):319-37.. 2012.
Epigenetic biomarkers in esophageal cancer.. Cancer letters.. 2012.
Fbw7 and p53 Cooperatively Suppress Advanced and Chromosomally Unstable Intestinal Cancer.. Molecular and cellular biology. 32(11):2160-7.. 2012.
TGF-β signaling promotes hepatocarcinogenesis induced by p53 loss.. Hepatology (Baltimore, Md.). 55(1):121-131.. 2012.
Variation in Age at Cancer Diagnosis in Familial versus Nonfamilial Barrett's Esophagus.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 21(2):376-383.. 2012.
Colorectal endoscopy, advanced adenomas, and sessile serrated polyps: implications for proximal colon cancer.. The American journal of gastroenterology. 107(8):1213-9.. 2012.
Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.. Genes, chromosomes & cancer. 51(4):393.. 2012.
Association of insulin and insulin-like growth factors with Barrett's oesophagus.. Gut. 61(5):665-672.. 2012.
DNA methylation profiling across the spectrum of HPV-associated anal squamous neoplasia.. PloS one. 7(11):e50533.. 2012.
Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry.. The Journal of molecular diagnostics : JMD. 13(3):271-81.. 2011.
Colorectal cancer molecular biology moves into clinical practice.. Gut. 60(1):116-29.. 2011.
DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses.. Epigenetics : official journal of the DNA Methylation Society. 6(12):1403-12.. 2011.
Epigenetics and colorectal cancer.. Nature reviews. Gastroenterology & hepatology. 8(12):686-700.. 2011.
Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations.. Annals of surgical oncology. 18(8):2338-47.. 2011.
TGF-beta inactivation and TGF-alpha overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer.. International journal of cancer. Journal international du cancer. 127(5):1060-71.. 2010.
Insights into the role of DNA methylation in disease through the use of mouse models.. Disease models & mechanisms. 3(5-6):290-7.. 2010.
A segregation analysis of Barrett's esophagus and associated adenocarcinomas.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 19(3):666-74.. 2010.
Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model.. Molecular carcinogenesis. 49(1):94-103.. 2010.
Linking epidemiology to epigenomics--where are we today? Cancer prevention research (Philadelphia, Pa.). 3(12):1505-8.. 2010.
Use of folic acid-containing supplements after a diagnosis of colorectal cancer in the Colon Cancer Family Registry.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 19(8):2023-34.. 2010.
TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway.. Gastroenterology. 136(5):1680-8.e7.. 2009.